Episode
Pharma Monopoly: The Battle for the Future of Medicines w/ Tahir Amin
- Published
- Jul 9, 2026
- Duration seconds
- 2143
- Processing state
not_requested- Canonical source
- https://parallaxviews.podbean.com/e/tamin7-9-26/
Actions
POST https://stenobird.com/v1/public/podcasts/parallax-views-w-j-g-michael-333302/episodes/pharma-monopoly-the-battle-for-the-future-of-medicines-w-tahir-amin/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/parallax-views-w-j-g-michael-333302/pharma-monopoly-the-battle-for-the-future-of-medicines-w-tahir-amin.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
👉 Pitch in on Patreon and fuel the future of free-thinking conversations. https://www.patreon.com/parallaxviews Also visit our returning sponsor Mike Swanson's Wall Street Window for the best financial and trading newsletter around:https://wallstreetwindow.com/ On this edition of Parallax Views, J.G. Michael is joined by Tahir Amin, founder and CEO of the Initiative for Medicines, Access & Knowledge (I-MAK) and co-author, with Rohit Malpani, of the new book Pharma Monopoly: The Battle for the Future of Medicines. Why have prescription drugs and life-saving medicines become so expensive? Is it simply the cost of innovation, or is the modern pharmaceutical industry built around monopoly power? In this brisk, information-packed conversation, Amin examines how patents, intellectual property law, global trade agreements, financialization, and neoliberal economic policies have reshaped the pharmaceutical industry and transformed medicine into one of the world's most profitable businesses. Drawing on the arguments in Pharma Monopoly, Amin explains how patent monopolies can delay generic competition, why the pharmaceutical industry's definition of "innovation" deserves closer scrutiny, how Wall Street increasingly influences drug development, and what the pandemic exposed about the global system for producing and distributing medicines. The conversation also explores the role of Third Way neoliberalism in the problems we face with the emergence of the pharma monopoly, criticisms of the medicines patent pool, the access-to-medicines movement, the influence of major philanthropic organizations (i.e.: Bill Gates and the Gates Foundation) and the issue of philanothro-capitalists, the financialization of the pharmaceutical industry, why the issues we are facing are not just lim…